Synergistic Experimental and Computational Investigation of the Bioorthogonal Reactivity of Substituted Aryltetrazines
作者:Umberto M. Battisti、Rocío García-Vázquez、Dennis Svatunek、Barbara Herrmann、Andreas Löffler、Hannes Mikula、Matthias Manfred Herth
DOI:10.1021/acs.bioconjchem.2c00042
日期:2022.4.20
18F-label highly reactive tetrazines based on a 3-(3-fluorophenyl)-Tz core structure. Herein, we report a kineticstudy on this versatile scaffold. A library of 40 different tetrazines was prepared, fully characterized, and investigated with an emphasis on second-order rate constants for the reaction with trans-cyclooctene (TCO). Our results reveal the effects of various substitution patterns and moreover
[Problem]
Provided is a compound which is useful as an agent for preventing and/or treating renal diseases.
[Means for Solution]
The present inventors have conducted extensive studies on compounds having a trypsin inhibitory action, and as a result, they have found that a guanidinobenzoic acid compound has a trypsin inhibitory action, thereby completing the present invention. The guanidinobenzoic acid compound of the present invention can be used as an agent for preventing and/or treating renal disease as an agent which will substitute low-protein diet therapy, and an agent for preventing and/or treating trypsin-related diseases, for example, pancreatitis, gastroesophageal reflux disease, hepatic encephalopathy, influenza, and the like.
[EN] NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING<br/>[FR] NOUVEAUX COMPOSÉS DE TÉTRAZINE POUR L'IMAGERIE IN VIVO
申请人:UNIV COPENHAGEN
公开号:WO2020108720A1
公开(公告)日:2020-06-04
The present invention relates to novel tetrazine compounds of formula I, wherein one of R1-R5 is 18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting molecule and a reporter molecule. The invention further relates to precursors to formula I, wherein one of R1-R5 is SnR3, B(OR)2, B(0H)2. Formula (I).